Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection

JAMA Ophthalmology

Volumn 132, Issue 4, 2014, Pages 484-486

  Fahim, Abigail T ^a   Khan, Naheed W ^a   Johnson, Mark W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OCRIPLASMIN;

A WAVE; ACUTE PANRETINAL DYSFUNCTION; ADULT; ANISOCORIA; ARTICLE; B WAVE; CASE REPORT; COLOR VISION; DISEASE SEVERITY; ELECTRORETINOGRAPHY; FEMALE; HUMAN; MACULAR THICKNESS; MIDDLE AGED; NIGHT BLINDNESS; OPHTHALMOSCOPY; OSCILLATORY POTENTIAL; PHOTORECEPTOR; PHOTORECEPTOR MEMBRANE; PHOTORECEPTOR OUTER SEGMENT; PRIORITY JOURNAL; PUPIL DISEASE; RETINA DISEASE; RETINA MACULA HOLE; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; VISION; VISUAL ACUITY; VISUAL FIELD CONSTRICTION; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VITREOMACULAR ADHESION; VITREOUS FLOATERS;

ACUTE DISEASE; ELECTRORETINOGRAPHY; EYE DISEASES; FEMALE; FIBRINOLYSIN; FIBRINOLYTIC AGENTS; HUMANS; INTRAVITREAL INJECTIONS; MIDDLE AGED; PEPTIDE FRAGMENTS; RETINAL DISEASES; RETINAL PERFORATIONS; RETROSPECTIVE STUDIES; TISSUE ADHESIONS; TOMOGRAPHY, OPTICAL COHERENCE; VISION DISORDERS; VISUAL ACUITY; VITREOUS BODY;

EID: 84898640525     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.8142     Document Type: Article

References (8)

1. US Food and Drug Administration. FDA approves Jetrea for symptomatic vitreomacular adhesion in the eyes [press release]. Updated October 18, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm324369.htm. Accessed August 3, 2013.
2. Hermel M, Dailey W, Hartzer MK. Efficacy of plasmin, microplasmin, and streptokinase-plasmin complex for the in vitro degradation of fibronectin and laminin. Curr Eye Res. 2010; 35 (5): 419-424.
3. Stalmans P, Benz MS, Gandorfer A, et al; MIVI-TRUST Study Group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012; 367 (7): 606-615.
4. Dermatologic and Ophthalmic Drugs Advisory Committee. Ocriplasmin (Jetrea) briefing document. July 26, 2012. http://www.fda.gov/downloads/ advisorycommittees/committeesmeetingmaterials/drugs/ dermatologicandophthalmicdrugs advisorycommittee/ucm313091.pdf. Accessed August 3, 2013.
5. Freund KB, Shah SA, Shah VP. Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin. Eye (Lond). 2013; 27 (6): 773-774.
6. Libby RT, Champliaud MF, Claudepierre T, et al. Laminin expression in adult and developing retinae. J Neurosci. 2000; 20 (17): 6517-6528.
7. Libby RT, Lavallee CR, Balkema GW, BrunkenWJ, Hunter DD. Disruption of laminin β2 chain production causes alterations in morphology and function in the CNS. J Neurosci. 1999; 19 (21): 9399-9411.
8. Sakuma T, Tanaka M, Mizota A, Inoue J, Pakola S. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. Invest Ophthalmol Vis Sci. 2005; 46 (9): 3295-3299.